CMIC: Blackstone Acquires Majority Stake in Japan’s Leading CRO

Blackstone, one of the world's largest private equity firms, has announced a definitive agreement to acquire a 60% majority stake in CMIC Co., Ltd, a Japanese Contract Research Organization (CRO) recognized as a leader in the clinical research domain. This strategic acquisition is part of Blackstone's ongoing commitment to invest in Japan's healthcare sector, where it has developed significant expertise and network. CMIC Co., founded in 1992, stands out as a pioneer in the CRO industry in Japan, collaborating with pharmaceutical and biotechnology firms to streamline and accelerate the development and market launch of medicines. Atsuhiko Sakamoto, Head of Private Equity at Blackstone Japan, emphasized the acquisition aligns with Blackstone's robust market presence in Japan and commitment to life sciences-related services. Furthermore, Kazuo Nakamura, the founder and CEO of CMIC HD, expressed enthusiasm about partnering with Blackstone to amplify CMIC's growth trajectory further. This move caps a particularly active year for Blackstone in Japan, marked by significant deals such as the acquisition of Irom Group and the carveout of Sony Payment Services. With over $1.1 trillion in assets under management, Blackstone's investment strategies span various sectors including real estate, private equity, and life sciences.